1357Identifying the undiagnosed AF patient through “Know Your Pulse” community pharmacy based events held in ten countries during Arrhythmia Alliance World Heart Rhythm Week 2017

Lobban, Trudie; Breakwell, N E; Hamedi, N; Antoniou, Sotiris; Costa, Fenelon; Tous, Salvador; Papastergiou, John; Derango, F; Griffiths, David J.; Chaumais, Marie-Camille; Viola, Réka; Ládová, Kateřina; Paulino, Ellena C.; Hersberger, Kurt E.; Freedman, Ben; Alliance, Arrhythmia

doi:10.1093/eurheartj/ehy565.1357

Cited by 4 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have highlighted community pharmacies as ideal partners due to their privileged location in the health care system and their easy access, provided adequately trained to undertake this activity. In fact, iPACT in partnership with A‐A/AFA has contributed to scale‐up pharmacist‐led awareness events where pulse palpation, in some cases allied with mobile ECG, is regularly organized in pharmacies around the world . Innovative technologies have also been described as a means to increase other allied professionals ability to engage in detection and confidently refer onward to physicians .…”

Section: Resultsmentioning

confidence: 99%

“…In fact, iPACT in partnership with A-A/AFA has contributed to scale-up pharmacist-led awareness events where pulse palpation, in some cases allied with mobile ECG, is regularly organized in pharmacies around the world. 24,25 Innovative technologies have also been described as a means to increase other allied professionals ability to engage in detection and confidently refer onward to physicians. 21,22 The AF-screen international collaboration has recognized this and extended their collaboration to include allied professionals, namely, nurses, pharmacists, and patient advocates.…”

Section: Identification Of High Risk Patients Through Screeningmentioning

confidence: 99%

See 1 more Smart Citation

The patient pathway in cardiovascular care: A position paper from the International Pharmacists for Anticoagulation Care Taskforce (iPACT)

Costa

Rydant²,

Antoniou

2020

Evaluation Clinical Practice

View full text Add to dashboard Cite

Background This position paper highlights the opportunistic integral role of the pharmacist across the patient pathway utilizing cardiovascular care as an example. The paper aims to highlight the potential roles that pharmacists worldwide can have (or already have) to provide efficient patient care in the context of interprofessional collaboration. Methods It results from a literature review and experts seeking advice to identify existing interventions and potential innovative interventions. We developed a conceptual framework highlighting seven critical phases in the patient pathway and for each of those listed some of the initiatives identified by our experts worldwide. Results Existing pharmacists' interventions in each of these phases have been identified globally. Various examples in the area of prevention and self‐management were found to exist for long; the contribution for early detection and subsequently to timely diagnosis were also quite clear; integration of care was perhaps one of the areas needing greater development, although interventions in secondary care were also quite common. Tertiary care and end of life interventions were found to often be left for other healthcare professionals. Conclusion On the basis of the findings, we can argue that much has been done but globally consider that pharmacists are still an untapped resource potentially useful for improved patient care.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Identification Of High Risk Patients Through Screeningmentioning

confidence: 99%

The patient pathway in cardiovascular care: A position paper from the International Pharmacists for Anticoagulation Care Taskforce (iPACT)

Costa

Rydant²,

Antoniou

2020

Evaluation Clinical Practice

View full text Add to dashboard Cite

show abstract

“…Thirteen studies have tested the feasibility of pharmacist-led atrial fibrillation screening programmes (Table 1). [4][5][6][7][8][9][10][11][12][13][14][15][16] Three of these also attempted to characterize atrial fibrillation by assessing symptoms 12 or using the CHA 2 DS 2 -VASc score to quantify stroke risk. 8,11 None of these studies have characterized atrial fibrillation by severity of atrial fibrillation burden or substrate severity.…”

Section: 'Cc' Confirm and Characterize Atrial Fibrillation : Pharmaci...mentioning

confidence: 99%

“…14 In one study, the AliveCor Kardia mobile single-lead ECG was only performed if abnormalities were first detected by a blood pressure (BP) monitor (Microlife AFIB). 15 One study did not specify the device used to generate the single-lead ECG, 12 and another study used the Microlife AFIB in isolation to detect atrial fibrillation. 10 Manual pulse palpation was performed in five studies, 5,6,9,12,16 and in one study 12 this was combined with a symptom and risk factor assessment.…”

Section: 'Cc' Confirm and Characterize Atrial Fibrillation : Pharmaci...mentioning

confidence: 99%

“…15 One study did not specify the device used to generate the single-lead ECG, 12 and another study used the Microlife AFIB in isolation to detect atrial fibrillation. 10 Manual pulse palpation was performed in five studies, 5,6,9,12,16 and in one study 12 this was combined with a symptom and risk factor assessment.…”

Section: 'Cc' Confirm and Characterize Atrial Fibrillation : Pharmaci...mentioning

confidence: 99%

See 1 more Smart Citation

Integrated Care for Atrial Fibrillation Management: The Role of the Pharmacist

Ritchie¹,

Penson²,

Akpan³

et al. 2022

The American Journal of Medicine

View full text Add to dashboard Cite

Screening for Heart Disease in the Age of Digital Health Technologies: Who, When, and How?

Richardson¹,

Hall²,

Hare³

et al. 2022

EMJ Cardiol

View full text Add to dashboard Cite

Heart disease affects much of the world’s population, yet many people have no idea that they could have something wrong with them. An opportunity therefore exists for targeted screening for conditions such as cardiovascular disease, heart rhythm changes, valvular heart disease, structural abnormalities, and more subtle, rarer inherited heart conditions. At the same time, the rapid development of digital health technologies and clinical support systems is providing patients and their doctors access to augmented intelligence solutions to diagnose these conditions. This article will focus on how the emerging field of digital health technology can aid screening for heart disease and explore its usefulness in disease specific and population specific groups.

show abstract

1357Identifying the undiagnosed AF patient through “Know Your Pulse” community pharmacy based events held in ten countries during Arrhythmia Alliance World Heart Rhythm Week 2017

Cited by 4 publications

References 0 publications

The patient pathway in cardiovascular care: A position paper from the International Pharmacists for Anticoagulation Care Taskforce (iPACT)

The patient pathway in cardiovascular care: A position paper from the International Pharmacists for Anticoagulation Care Taskforce (iPACT)

Integrated Care for Atrial Fibrillation Management: The Role of the Pharmacist

Screening for Heart Disease in the Age of Digital Health Technologies: Who, When, and How?

Contact Info

Product

Resources

About